In the most recent Intergovernmental Working Meeting on Drug Compounding, Nov. 7-8, 2023, FDA and state regulators identified three actions items. This page contains a summary of those action items and how FDA has responded.
Similar Posts
FDA In Brief: FDA provides guidance on improving the agency’s interactions with product developers to make the drug development process more informed and efficient
FDA announces two new guidances to support enhanced communication with drug developers, help make the development process more informed and efficientFDA Awards First-Ever National Priority Vouchers to Nine Sponsors
The U.S. Food and Drug Administration today announced 9 voucher recipients under the new Commissioner’s National Priority Voucher (CNPV) pilot program.Sanofi S.p.A. – 05/22/2023
Sanofi S.p.A. – 05/22/2023. Country: Italy. Record Type: 483Advanced Nutriceuticals LLC. Indianapolis, IN. 483 issued 11/22/2024
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 11/22/2024
Short Title (70 char) Advanced Nutriceuticals LLC. Indianapolis, IN. 483 issued 11/22/2024
FEI Number 3010039017
Firm Name Advanced Nutriceuticals LLC
Record Type 483
State IN
Establishment Type Steri2023 Meeting Materials, Cardiovascular and Renal Drugs Advisory Committee
This page contains the meeting materials for the Cardiovascular & Renal Drugs Advisory Committee meetings for 2023.Nephron Sc Inc. West Columbia, SC. 483 issued 08/22/2025
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 08/22/2025
Short Title (70 char) Nephron Sc Inc. West Columbia, SC. 483 issued 08/22/2025
FEI Number 3010892830
Firm Name Nephron Sc Inc
Record Type 483
State SC
Establishment Type Sterile Drug Manufacturing